(2005). Adenosine in tissue protection and tissue re generation. Mol Pharmacol
(2008). Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones. Pflugers Arch
(2004). Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis
(1996). Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
(2002). Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
(2000). Borea PA: A(2A) adenosine receptors in human peripheral blood cells.
(2005). Cominelli F: Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology
(1999). CS: Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology.
(2006). Cuzzocrea S: Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury.
(2010). Cuzzocrea S: Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. J Biol Regul Homeost Agents
(2009). Cuzzocrea S: The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock
(2005). CY: JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis
(2007). de Mendonça A: Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol
(2006). Degenerative and spontaneous regenerative processes after spinal cord injury.
(2005). EA: Characterization of a new rat model of experimental combined neurotrauma. Shock
(1999). Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation.
(2006). Fehlings MG: Pharmacological approaches to repair the injured spinal cord.
(1998). Hasko G: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists.
(2000). HI: Developmental expression of OSP/claudin-11.
(2006). HS: Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury.
(2000). Hughes MG: Adenosine release upon spinal cord injury. Brain Res
(2002). JA: Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg
(2002). JA: Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit.
(2010). JF: Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury.
(1994). Kouchoukos NT: Dextrorphan inhibits the release of excitatory amino acids during spinal cord ischemia. Ann Thorac Surg
(1995). Kouchoukos NT: Profound systemic hypothermia inhibits the release of neurotransmitter amino acids in spinal cord ischemia. J Thorac Cardiovasc Surg
(2004). Marcillo A: The pathology of human spinal cord injury: defining the problems.
(2004). Molecular mechanisms of glutamatedependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci
(2006). Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience
(1998). MP: Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med
(2004). Nö renberg W, Illes P: Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology
(1994). Nomenclature and classification of purinoceptors. Pharmacol Rev
(1997). Olsson Y: Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord.
(1998). Ongini E: Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther
(1993). Pathophysiology of spinal cord trauma. Ann Emerg Med
(2006). PB: Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis.
(2008). Pedata F: Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des
(2009). Pedata F: Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain
(2000). Pedata F: Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport
(1999). Pedata F: Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport
(2006). Pedata F: The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res
(2003). Pedata F: The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res
(2006). Perinatal white matter injury: the changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev
(2003). Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin.